- Home
- All Stock List
- NSE
- Alivus Life Sciences Ltd Share Price
Alivus Life Sciences Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap
1,206.00
25.10 (2.13%)
-
Outperforms Index
46.85%
Return (1Y)
Beaten Nifty 500 by 36.98%
-
More Volatile
2.86%
Standard Deviation (1Y)
Higher than Nifty 500 by 1.78%
-
Consistent Performer
7/12
Months
beaten Nifty 500
-
AxisDirect View
No View
1,335
756
News & Announcements
-
Alivus Life Sciences to hold board meeting
7 days ago
-
Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Consequent to the allotment, the paid up equity share capital has increased to 12,26,29,148 equity shares of Rs. 2 each aggregating to Rs. 24,52,58,296/-.
Powered by Capital Market - Live News
-
Alivus Life Sciences standalone net profit rises 15.32% in the December 2024 quarter
23 - Jan - 2025 12:00 | 113 days ago
Net profit of Alivus Life Sciences rose 15.32% to Rs 136.96 crore in the quarter ended December 2024 as against Rs 118.77 crore during the previous quarter ended December 2023. Sales rose 12.05% to Rs 641.84 crore in the quarter ended December 2024 as against Rs 572.80 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 641.84 572.80 12 OPM % 29.65 30.13 - PBDT 200.31 173.87 15 PBT 185.15 160.69 15 NP 136.96 118.77 15 Powered by Capital Market - Live News
-
Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Consequent to the allotment, the paid up equity share capital has increased to 12,26,29,148 equity shares of Rs. 2 each aggregating to Rs. 24,52,58,296/-.
Powered by Capital Market - Live News
-
Alivus Life Sciences standalone net profit rises 15.32% in the December 2024 quarter
23 - Jan - 2025 12:00 | 113 days ago
Net profit of Alivus Life Sciences rose 15.32% to Rs 136.96 crore in the quarter ended December 2024 as against Rs 118.77 crore during the previous quarter ended December 2023. Sales rose 12.05% to Rs 641.84 crore in the quarter ended December 2024 as against Rs 572.80 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 641.84 572.80 12 OPM % 29.65 30.13 - PBDT 200.31 173.87 15 PBT 185.15 160.69 15 NP 136.96 118.77 15 Powered by Capital Market - Live News
-
Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25.
For Q3FY25, EBITDA was at Rs 200.8 crore, a growth of 15.2% YoY. EBITDA margin stood at 31.3%, up 90 bps YoY.
On segmental front, the revenue from Generic API grew by 16.9% YoY to Rs 596.6 crore in Q3 FY25 while revenue from CDMO declined 14.29% YoY to Rs 30 crore in Q3 FY25.
Yasir Rawjee, MD & CEO, Alivus Life Sciences, said, “The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences. I am pleased to report that our Q3 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth.
Alivus Life Sciences (Formerly Glenmark Life Sciences) is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. It has a diversified portfolio of 161 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).
Powered by Capital Market - Live News
-
Alivus Life Sciences to hold board meeting
7 days ago
-
Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Consequent to the allotment, the paid up equity share capital has increased to 12,26,29,148 equity shares of Rs. 2 each aggregating to Rs. 24,52,58,296/-.
Powered by Capital Market - Live News
-
Alivus Life Sciences standalone net profit rises 15.32% in the December 2024 quarter
23 - Jan - 2025 12:00 | 113 days ago
Net profit of Alivus Life Sciences rose 15.32% to Rs 136.96 crore in the quarter ended December 2024 as against Rs 118.77 crore during the previous quarter ended December 2023. Sales rose 12.05% to Rs 641.84 crore in the quarter ended December 2024 as against Rs 572.80 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 641.84 572.80 12 OPM % 29.65 30.13 - PBDT 200.31 173.87 15 PBT 185.15 160.69 15 NP 136.96 118.77 15 Powered by Capital Market - Live News
-
Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25.
For Q3FY25, EBITDA was at Rs 200.8 crore, a growth of 15.2% YoY. EBITDA margin stood at 31.3%, up 90 bps YoY.
On segmental front, the revenue from Generic API grew by 16.9% YoY to Rs 596.6 crore in Q3 FY25 while revenue from CDMO declined 14.29% YoY to Rs 30 crore in Q3 FY25.
Yasir Rawjee, MD & CEO, Alivus Life Sciences, said, “The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences. I am pleased to report that our Q3 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth.
Alivus Life Sciences (Formerly Glenmark Life Sciences) is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. It has a diversified portfolio of 161 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).
Powered by Capital Market - Live News
-
Alivus Life Sciences to hold board meeting
7 days ago
-
Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Consequent to the allotment, the paid up equity share capital has increased to 12,26,29,148 equity shares of Rs. 2 each aggregating to Rs. 24,52,58,296/-.
Powered by Capital Market - Live News
-
Alivus Life Sciences standalone net profit rises 15.32% in the December 2024 quarter
23 - Jan - 2025 12:00 | 113 days ago
Net profit of Alivus Life Sciences rose 15.32% to Rs 136.96 crore in the quarter ended December 2024 as against Rs 118.77 crore during the previous quarter ended December 2023. Sales rose 12.05% to Rs 641.84 crore in the quarter ended December 2024 as against Rs 572.80 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 641.84 572.80 12 OPM % 29.65 30.13 - PBDT 200.31 173.87 15 PBT 185.15 160.69 15 NP 136.96 118.77 15 Powered by Capital Market - Live News
-
Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Consequent to the allotment, the paid up equity share capital has increased to 12,26,29,148 equity shares of Rs. 2 each aggregating to Rs. 24,52,58,296/-.
Powered by Capital Market - Live News
-
Alivus Life Sciences standalone net profit rises 15.32% in the December 2024 quarter
23 - Jan - 2025 12:00 | 113 days ago
Net profit of Alivus Life Sciences rose 15.32% to Rs 136.96 crore in the quarter ended December 2024 as against Rs 118.77 crore during the previous quarter ended December 2023. Sales rose 12.05% to Rs 641.84 crore in the quarter ended December 2024 as against Rs 572.80 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 641.84 572.80 12 OPM % 29.65 30.13 - PBDT 200.31 173.87 15 PBT 185.15 160.69 15 NP 136.96 118.77 15 Powered by Capital Market - Live News
-
Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25.
For Q3FY25, EBITDA was at Rs 200.8 crore, a growth of 15.2% YoY. EBITDA margin stood at 31.3%, up 90 bps YoY.
On segmental front, the revenue from Generic API grew by 16.9% YoY to Rs 596.6 crore in Q3 FY25 while revenue from CDMO declined 14.29% YoY to Rs 30 crore in Q3 FY25.
Yasir Rawjee, MD & CEO, Alivus Life Sciences, said, “The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences. I am pleased to report that our Q3 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth.
Alivus Life Sciences (Formerly Glenmark Life Sciences) is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. It has a diversified portfolio of 161 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).
Powered by Capital Market - Live News
Stock Trivia
MF shareholding in Glenmark Life Sciences Ltd has increased by 11.39% since past 3 Months
Promoter shareholding in Glenmark Life Sciences Ltd has decreased by -9.48% since past 1 Year
MF shareholding in Glenmark Life Sciences Ltd has increased by 11.39% since past 3 Months
FII shareholding in Glenmark Life Sciences Ltd has increased by 31.08% since past 1 Year
MF shareholding in Glenmark Life Sciences Ltd has increased by 287.07% since past 1 Year
Promoter shareholding in Glenmark Life Sciences Ltd has decreased by -9.48% since past 1 Year
MF shareholding in Glenmark Life Sciences Ltd has increased by 11.39% since past 3 Months
Promoter shareholding in Glenmark Life Sciences Ltd has decreased by -9.48% since past 1 Year
